ArticleBMC public health2025
Cervical cancer screening and its associated factors among women of reproductive age in senegal: evidence from 2023 continuous demographic and health survey in Senegal.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cultural and traditional influences on cervical cancer screening uptake in Nigeria and other West African countries.BMC public health · 2026Pooled it
- Prevalence and determinants of cervical cancer screening among women aged 30-49 years in Nigeria: A population-based cross-sectional study.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn 2022, approximately 660,000 new cases and 350,000 deaths from cervical cancer were reported worldwide, making it the fourth most common malignancy among women globally.
objectiveTo determine the prevalence and the factors associated with cervical cancer screening among women of reproductive age in Senegal.
methodThe study analyzed secondary data from the 2023 Continuous Demographic and Health Survey. The study included a weighted sample of 16,583 women. The study used the “svy” command in Stata to assign the sample weight. Multivariable logistic regression was used to assess significant factors associated cervical cancer screening and statistical significance was set at a 5% significance level.
resultsIn Senegal, 9.5% of women of reproductive age had undergone cervical cancer screening (95% CI = 8.67, 10.41). The prevalence cervical cancer screenings ranged greatly by location, from 2.4% in Matam to 14.6% in Thies. The results revealed that factors associated with cervical cancer screening among women of reproductive age included being aged 30-49 (AOR = 1.54, 95% CI = 1.25, 1.90), being married (AOR = 2.97, 95% CI = 1.92, 4.60) or separated (AOR = 2.48, 95% CI = 1.55, 3.97), belonging to middle (AOR = 1.50, 95% CI = 1.17, 1.91) and rich wealth indices (AOR = 1.66, 95% CI = 1.27, 2.16), being employed (AOR = 1.27, 95% CI = 1.05, 1.54), having health insurance (AOR = 1.37, 95% CI = 1.11, 1.69), having 1-2 children (AOR = 1.80, 95% CI = 1.28, 2.52), having 3 or more children (AOR = 1.95, 95% CI = 1.34, 2.85), having experienced a terminated pregnancy (AOR = 1.38, 95% CI = 1.15, 1.65), visiting health facility (AOR = 1.59, 95% CI = 1.33, 1.91), and watching television (AOR = 1.30, 95% CI = 1.01, 1.67).
conclusionThe study highlights low screening prevalence of 9.5%, compared to the WHO recommendation of 70%. Factors such as age, marital status, and wealth status, employment, significantly impacted screening rates. The study underscores the need for tailored programs aimed at increasing cervical cancer screening, including mobile screening initiatives, increased outreach programs, and enhanced health insurance coverage for all women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.